Group 1 - The company held its first H-share class shareholders' meeting for 2025 on July 7, 2025, in Beijing, where the board of directors proposed a general authorization for the repurchase of H shares [1][2] - The proposal requires approval from three shareholder meetings: the 2024 annual general meeting, the first A-share class meeting of 2025, and the first H-share class meeting of 2025, with more than two-thirds of the voting rights present at each meeting needed for approval [1][2] - The voting results showed that 100% of the H-share ordinary shareholders present voted in favor of the proposal, with no votes against or abstentions [2] Group 2 - The meeting was convened by the board of directors and chaired by the chairwoman, Ms. Shi Wenling, following legal and procedural requirements as per the Company Law and Securities Law [2][3] - The lawyers present confirmed that the meeting's procedures, participant qualifications, and voting results complied with relevant laws and regulations, deeming the resolutions passed as legal and valid [3]

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 18.77 yuan, with a PE ratio of 56.31, marking a new low in 273 days, and a total market capitalization of 7.2 billion yuan [1] - The average PE ratio for the medical device industry is 51.42, with a median of 37.44, placing Chunzhi Medical at the 88th position in the industry ranking [1] - As of the first quarter of 2025, 13 institutions hold shares in Chunzhi Medical, including 8 funds, with a total holding of 31.63 million shares valued at 429 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] - The latest performance report for the first quarter of 2025 shows that the company achieved revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]

北京市万商天勤律师事务所 关于 北京市春立正达医疗器械股份有限公司 2025 年第一次 H 股类别股东大会的 法律意见书 北京市朝阳区建国门外大街 8 号北京国际财源中心 A 座 32 层 100022 电话：+86 10 82255588 www.vtlaw.cn 北京 深圳 上海 成都 武汉 西安 长沙 杭州 海口 南京 广州 昆明 福州 重庆 天津 合肥 香港(联营) 北京市万商天勤律师事务所 关于北京市春立正达医疗器械股份有限公司 2025 年第一次 H 股类别股东大会的 法律意见书 致：北京市春立正达医疗器械股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》及中国证券监督管理 委员会《上市公司股东会规则》（以下称"《股东会规则》"）等法律、法规和规范性文 件的规定，北京市万商天勤律师事务所（以下称"本所"）接受北京市春立正达医疗 器械股份有限公司（以下称"公司"）的委托，指派律师参加公司 2025 年第一次 H 股 类别股东大会（以下称"本次股东大会"），并出具法律意见。 本所律师同意将本法律意见书随公司本次股东大会决议一并予以公告，并依法对 本法律意见书承担相应的责任。 本所律师根 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-029 北京市春立正达医疗器械股份有限公司 2025年第一次 H 股类别股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 涉及类别股东大会审议的《关于授予董事会回购 H 股的一般性授权的议案》， 此议案需要经过 2024 年年度股东大会、2025 年第一次 A 股类别股东大会、2025 年第一次 H 股类别股东大会上述 3 个股东大会出席会议的股东分别投票，每个 股东大会针对此议案需经出席该会议股东所持表决权的三分之二以上审议通过。 其中，2024 年年度股东大会、2025 年第一次 A 股类别股东大会在 2025 年 6 月 26 日已经分别审议通过该议案，2025 年第一次 H 股类别股东大会于 2025 年 7 月 7 日审议通过，该议案获审议通过，敬请投资者注意。 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 7 日 （二） 股东大会召开的地点：北京市通州区通州经 ...

Market Overview - The Hang Seng Index fell by 0.45%, down 107 points, closing at 23,808 points, while the Hang Seng Tech Index decreased by 0.15% [1] - Early trading volume in Hong Kong stocks reached HKD 109.5 billion [1] Stablecoin Regulation - The Hong Kong Monetary Authority plans to release guidelines for stablecoin regulations this month, aiming to issue licenses within the year [1] - Stocks related to stablecoins saw significant gains, with Guotai Junan International rising by 8.2%, ZhongAn Online increasing by 5.64%, and Yike rising over 9% [1] New Tea Beverage Market - A subsidy war in the takeaway market has ignited the new tea beverage sector, with Guming and Cha Baidao both rising over 9% [1] Digital Health Services - Health Road saw its stock rise over 9% as its controlling shareholder voluntarily extended the lock-up period, focusing on a digital health service platform [1] Gaming Industry - Morgan Stanley reported that Macau's gaming revenue in June increased by 19% year-on-year to MOP 21.1 billion, exceeding analyst predictions by 9% [1] - Gaming stocks continued their upward trend, with Amax Holdings up 3.7%, Melco International Development up 1.6%, and MGM China up 2.1% [1] Medical Device Sector - In response to China's reciprocal restrictions on EU medical devices, the National Medical Products Administration issued support for high-end medical devices [1] - Medical device stocks experienced broad gains, with Spring Medical up 1.86%, Yongsheng Medical up 7.27%, and Xinwei Medical-B up 5.5% [1] Company Developments - China Rare Earth Holdings plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Jihong Co. saw its stock rise over 10%, with a projected over 55% year-on-year increase in net profit attributable to shareholders for the first half of the year [3] - H&H International Holdings is expected to see a decline in net profit by 45% to 65% for the first half of the year, resulting in a drop of over 6% in its stock price [4]

Market Overview - The US stock market was closed on July 4th for Independence Day [1] Hong Kong Stock Market Highlights - Yum China (09987) rose over 3% after announcing the establishment of an innovation fund to convert operational needs into practical applications [2] - H&H International Holdings (01112) fell over 7%, expecting a 45% to 65% decline in net profit for the first half of the year [2] - China Rare Earth Holdings (03788) surged nearly 9% as it plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Health Road (02587) jumped over 18% as its controlling shareholder voluntarily extended the lock-up period, focusing on digital health services [2] - Smoore International (06969) increased over 5% with the launch of Glo Hilo in Japan, maintaining high profit margins [2] - Tencent Music (01698) rose nearly 3% as institutions noted that recent acquisition plans would enhance overall content supply [2] - Jihong Co., Ltd. (02603) surged over 7%, with a projected net profit increase of over 55% year-on-year for the first half [2] - Solar stocks collectively declined, with Xinyi Solar (00968) down 4.86%, Fuyao Glass (06865) down 3.88%, New Energy (01799) down 3.19%, and Xinyi Glass (00868) down 2.64% [2] Other Notable Movements - Kuaishou-W (01024) rose over 3% as it plans to launch a live streaming initiative across multiple cities to create a collaborative ecosystem [3] - Gold stocks faced pressure, with Shandong Gold (01787) down 5.09%, China Gold International (02099) down 3.44%, Lingbao Gold (03330) down 2.68%, and Chifeng Jilong Gold (06693) down 2.33% [3] - China Shipbuilding Defense (00317) increased over 3% after the approval of a merger and acquisition restructuring plan, optimizing resources in the shipbuilding industry [3] - Medical device stocks saw a broad increase, with Spring Medical (01858) up 6.36%, Yongsheng Medical (01612) up 7.27%, Xinwei Medical-B (06609) up 3.55%, and Microneuroscience (02172) up 1.12% [3] - Some stablecoin concept stocks rose, with Victory Securities (08540) up 6.9%, Guotai Junan International (01788) up 5.15%, Yika (09923) up 2.59%, and China Everbright Holdings (00165) up 1.96% [3] - SF Express City (09699) rose nearly 7% amid intensified competition in the food delivery sector, with expectations of increased order volume [3] - HSSP International (03626) fell over 20% after being named by the Hong Kong Securities and Futures Commission for high stock concentration [3] Strategic Partnerships and New Listings - Shengye (06069) opened nearly 15% higher after forming a strategic partnership with Stand Robot to enhance its robotics industry chain [4] - Beverage stocks opened high, with Cha Bai Dao (02555) up 15%, Nayuki's Tea (02150) up 9.87%, Gu Ming (01364) up 5.77%, Hu Shang Ayi (02589) up 2.99%, and Mixue Group (02097) up 2.92% [4] - FWD Group (01828) had a flat opening on its first day of listing, being a life insurance company under Li Zeqiang's control [4]

Group 1 - The A-share medical device sector experienced a short-term surge, with Baolait rising over 17% [1] - Other stocks such as Jinan Development, Yangpu Medical, Tianyi Medical, Diri Medical, Guanhao Biological, and Chunli Medical also saw increases [1] - The rise in stock prices is attributed to the Chinese government's procurement measures affecting medical devices imported from the European Union [1]

FF301 | 383,568,500 | | --- | | 本月底法定/註冊股本總額： RMB | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688236 | 說明 | | 於上海證券交易所上市的A股 | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 288,428,000 | RMB | | 1 RMB | | 288,428,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 288,428,000 | RMB | | 1 RMB | | 288,428,000 | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | ...

核查意见 华泰联合证券有限责任公司关于 北京市春立正达医疗器械股份有限公司 使用自有资金、银行承兑汇票等方式支付募投项目所需资金 公司已对募集资金采取了专户存储，并按规定与保荐机构、专户存储募集资 金的相关银行签署了募集资金专户监管协议。监管协议对公司、保荐机构及存放 募集资金相关银行的相关责任和义务进行了明确约定，明确了各方的权利和义 务，对募集资金的使用实行严格的审批手续，以保证专款专用。 二、募集资金投资项目的使用情况 根据《北京市春立正达医疗器械股份有限公司首次公开发行股票并在科创板 上市招股说明书》，以及经公司于 2022 年 1 月 18 日召开的第四届董事会第十六 1 并以募集资金等额置换的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"）作为北京市春立 正达医疗器械股份有限公司（以下简称"春立医疗"或"公司"）首次公开发行 股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业务管 理办法》、《科创板上市公司持续监管办法（试行）》、《上海证券交易所科创 板股票上市规则》、《上市公司募集资金监管规则》等有关规定，对春立医疗使 用自有资金、银行承兑汇票等方式支付募投项目所需 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-026 二、募集资金投资项目的使用情况 根据《北京市春立正达医疗器械股份有限公司首次公开发行股票并在科创板 上市招股说明书》，以及经公司于 2022 年 1 月 18 日召开的第四届董事会第十六 次会议和第四届监事会第四次会议，会议审议通过了《关于调整募集资金投资项 目拟投入募集资金金额的议案》，公司对募集资金投资项目拟投入募集资金金额 进行调整；后续公司于 2023 年 8 月 30 日召开第五届董事会第二次会议和第五届 监事会第二次会议，审议通过了《关于部分募投项目变更的议案》，公司调整后 的募集资金具体分配情况如下： 单位：万元 | 序号 | 募集资金 | 项目投资 | 调整前拟投入募 | 调整后拟投入募 | | --- | --- | --- | --- | --- | | | 投资项目 | 总额 | 集资金金额 | 集资金金额 | | 1 | 骨科植入物及配套材 | 94,470.38 | 86,000.00 | 46,000.00 | | | 料综合建设项目 | | | | | 2 | 研发中心建设项目 | 70,806.59 | 6 ...